Related Experiment Video
Updated: Oct 7, 2025

11:22
Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
30.1K
Accurate diagnosis of atopic dermatitis by combining transcriptome and microbiota data with supervised machine
Ziyuan Jiang1, Jiajin Li2, Nahyun Kong3
1Department of Automation, Tsinghua University, Beijing, 100084, China.
Scientific Reports
|January 8, 2022
Summary
This study developed an automated pipeline using machine learning to diagnose atopic dermatitis (AD) by analyzing gene and gut bacteria data. The system accurately identified AD, highlighting potential biomarkers for prediction.
Area of Science:
- Genomics and Microbiology
- Computational Biology
- Dermatology
Background:
- Atopic dermatitis (AD) is a prevalent childhood skin condition requiring expert diagnosis.
- Emerging research links gut microbiome and host gene interactions to AD pathogenesis.
- Current diagnostic methods for AD can be complex and require specialized dermatological expertise.
Purpose of the Study:
- To create an accurate, automated diagnostic pipeline for atopic dermatitis (AD).
- To leverage host transcriptome and gut microbiota data for AD risk prediction.
- To identify novel genetic and microbial biomarkers associated with AD.
Main Methods:
- Utilized transcriptome and microbiota data from 161 subjects (AD patients and healthy controls).
- Developed and trained a machine learning classifier to predict AD risk.
- Performed feature selection to identify predictive genes and microbial taxa.
Main Results:
- The machine learning classifier achieved an average F1-score of 0.84 in differentiating AD patients from healthy individuals.
- Identified 35 predictive genes and 50 predictive microbiota features for AD.
- Discovered at least three genes and three microorganisms with direct or indirect associations with AD.
Conclusions:
- The developed omics-based pipeline demonstrates high accuracy in AD prediction.
- Identified genes and microbiota features may serve as novel biomarkers for AD.
- Further validation in independent cohorts is necessary to confirm the utility of these biomarkers.

